Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™

28.08.2025 - 18:04:42

Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™. Piramal Pharma Solutions Italy United States of America Switzerland France United Kingdom Germany Canada India Austria

Piramal Pharma Solutions extended its robust CDMO capabilities to George Medicines to develop WIDAPLIK.WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.WIDAPLIK contains three medicines that are clinically proven to reduce blood pressure: telmisartan, amlodipine, and indapamide.| LinkedIn

For Investor Queries:
Gagan Borana
Investor Relations & Enterprise Risk Management
gagan.borana@piramal.com

About George Medicines

George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide.

George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia's leading life sciences venture capital firm.

For more information, please visit www.george-medicines.com.

Logo: https://mma.prnewswire.com/media/1726186/5481845/Piramal_Pharma_Solutions_Logo.jpg
Photo: https://mma.prnewswire.com/media/2760195/Piramal_CEO.jpg
Photo: https://mma.prnewswire.com/media/2760196/CEO_George_Medicines.jpg
Logo: https://mma.prnewswire.com/media/2760194/George_Medicines_Logo.jpg

Media Contacts:
David Daley/Lindsey Neville/Tom Daniel
ICR Healthcare
georgemedicines@icrhealthcare.com
+44 (0) 203 709 5700